Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

What Is the Appropriate Price for Platelet‐Rich Plasma Injections for Knee Osteoarthritis? A Cost‐Effectiveness Analysis Based on Evidence From Level I Randomized Controlled Trials

Arthroscopy The Journal of Arthroscopic and Related Surgery(2020)10.1016/j.arthro.2020.02.004Source: DataRank Database

What Is the Appropriate Price for Platelet‐Rich Plasma Injections for Knee Osteoarthritis? A Cost‐Effectiveness Analysis Based on Evidence From Level I Randomized Controlled Trials is a research paper published in Arthroscopy The Journal of Arthroscopic and Related Surgery (2020). On theSindex it has a DataRank of 0. It has been cited 44 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

44 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (11 grants)Topics (13)IDs (PubMed)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

William J. Rubenstein ORCID,Brian J. Cole ORCID,C. Benjamin ORCID,Brian T. Feeley ORCID,Drew A. Lansdown ORCID

Live enrichment

PubMed:32061971

Arthroscopy Association of North America

Zimmer

Pacira Pharmaceuticals

Anika Therapeutics

Arthrex

Arthritis Foundation

GE Healthcare

Histogenics

Biomet

Genzyme

National Institutes of Health

MeSH Terms

HumansOsteoarthritis, KneeHyaluronic AcidPain MeasurementTreatment OutcomeInjections, Intra-ArticularSeverity of Illness IndexCommerceCost-Benefit AnalysisMedicareUnited StatesPlatelet-Rich PlasmaRandomized Controlled Trials as Topic